tafasitamab + idelalisib

Tafasitamab + idelalisib is an investigational combination therapy for relapsed or refractory chronic lymphocytic leukemia (CLL), particularly in patients who have failed prior treatment with a Bruton's tyrosine kinase inhibitor[1][3][4]. **Tafasitamab** is a humanized monoclonal antibody targeting CD19, inducing programmed cell death in malignant B cells and enhancing immune responses through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis[5][7]. **Idelalisib** is a selective small molecule inhibitor of the delta isoform of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3Kδ), which is important for B-cell survival, trafficking, and proliferation[2]. The rationale for combination is to target malignant B cells via both direct immunologic killing (CD19) and inhibition of survival/proliferation signaling (PI3Kδ). Clinical studies suggest high overall response rates and undetectable minimal residual disease in a subset of patients with R/R CLL[1][3][4]. This regimen remains investigational and not yet approved for standard care.

Other names

tafasitamab-cxixidelalisib